At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated ...

Baxdrostat is an investigational highly selective, oral, small molecule designed to inhibit aldosterone synthase.

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

A promising new drug may finally bring hope to people suffering from a common but often overlooked cause of high blood ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...